Before authorizing publication of the preceding report the Council submitted it to the Bristol-Myers Company in order to give that company the opportunity of revising its method of marketing Ziratol. In reply the company enlarged on its withdrawal (on “our own initiative”) of the claim that Ziratol had a phenol-coefficient of over ten when this claim was shown to be incorrect “by authoritative sources.” One wonders whether this is a euphemistic reference to the proceedings of the federal authorities under the Insecticide Act against the Bristol-Myers Company, just made public,[121] because of the false claims made for the germicidal efficiency of Ziratol. This prosecution resulted in the seizure and condemnation of two lots of this proprietary which had passed in interstate commerce. [121] U. S. Dept. of Agric., Insecticide and Fungicide Board, Service and Regulatory Announcements, No. 16, issued Aug. 8, 1917. _No. 244_, Misbranding of “Ziratol.” U. S. _v._ 100 bottles, more or less, of “Ziratol”; consent decree of condemnation and forfeiture; product ordered released on bond, p. 248. _No. 256_, Misbranding of “Ziratol.” U. S. _v._ 936 bottles and 6 jugs of Ziratol, consent decree of condemnation and forfeiture; product ordered released on bond, p. 260. The Bristol-Myers Company in replying to the Council’s report made no offer to declare the exact composition of Ziratol, to state the actual phenol-coefficient, or to remove the other objections pointed out in the report of the Council. In other words, the Bristol-Myers Company has abandoned a definite but false claim of high germicidal power--a claim which subjected the firm to federal prosecution--and has substituted therefor indefinite statements which do not define the actual germicidal efficiency of Ziratol.--(_From The Journal A. M. A., Oct. 6, 1917._) GONOSAN Report of the Council on Pharmacy and Chemistry The Council has adopted the following report on Gonosan and authorized its publication. W. A. Puckner, Secretary. Gonosan (Riedel and Company, Inc., New York City) comes in the form of capsules, each said to contain 5 minims of a mixture composed of oil of sandalwood 80 per cent., and 20 per cent. of alpha- and beta-resin of kava, isolated by a patent process. The mixture, as the name implies, is intended for the treatment of gonorrhea. This proprietary preparation was under consideration by the Council at various times from 1905 to 1910. During this time, the Council agreed to accept the preparation if the suggestive name was changed, the therapeutic exaggerations abandoned, and the drug kava admitted to New and Nonofficial Remedies. The name was not changed, the other questions were left open, and the preparation was not accepted.